Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Core Scientific, Inc. Tranche 2 Warrants (CORZZ) provides access to regulatory documents that explain how these warrants relate to Core Scientific’s common stock and broader capital structure. Core Scientific’s filings under the Exchange Act identify CORZZ as a class of warrants listed on the Nasdaq Global Select Market, each whole warrant exercisable for one share of Core Scientific common stock at a specified exercise price.
Through Forms 8-K and other filings, Core Scientific discloses material events affecting CORZZ, such as the satisfaction of trading price conditions that make tranche 2 warrants exercisable for a defined period. These filings describe the warrant terms, including exercise prices and the number of warrants outstanding, and may reference related press releases furnished as exhibits. Investors can review these documents to understand when and how CORZZ can be exercised and how many shares of common stock each warrant represents.
Filings also place CORZZ in the context of Core Scientific’s capital structure and corporate transactions. In connection with the company’s emergence from Chapter 11 reorganization, SEC disclosures outline the issuance of new common stock, tranche 1 warrants, tranche 2 warrants and other securities. Later 8-K filings describe an Agreement and Plan of Merger under which CoreWeave, Inc. is expected to acquire Core Scientific in an all-stock transaction. These documents explain how each share of Core Scientific common stock would convert into CoreWeave Class A common stock and how existing warrants, including tranche 2 warrants, would be adjusted into new warrants exercisable for CoreWeave shares based on an exchange ratio.
On Stock Titan, users can review real-time updates from EDGAR alongside AI-powered summaries that highlight key points from Core Scientific’s 8-Ks and other filings. These summaries help clarify the implications of warrant-related disclosures, merger terms, and other regulatory information without requiring readers to parse every technical detail. The filings page also surfaces information on registered securities, including CORZ, CORZW and CORZZ, so investors can see how the different instruments interact within Core Scientific’s disclosed capital structure.
Core Scientific, Inc. received a Schedule 13G showing that four affiliated Susquehanna entities together report beneficial ownership of 17,376,097 shares of common stock, or 5.6% of the company, as of the event date 12/31/2025.
The percentage is based on 310,061,300 shares outstanding as of October 20, 2025, as disclosed in the company’s Form 10-Q. Holdings include common stock, options and warrants across G1 Execution Services, SIG Brokerage, Susquehanna Investment Group and Susquehanna Securities.
Each firm has sole voting and dispositive power over its own positions and shared power over all reported shares. They state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Core Scientific.
Barclays PLC has disclosed a small ownership stake in Core Scientific Inc. The filing reports that Barclays beneficially owns 1,302,387 shares of Core Scientific common stock, representing 0.42% of the outstanding class.
Barclays reports 1,298,420 shares with sole voting and dispositive power and 3,967 shares with shared voting and dispositive power. The shares are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Core Scientific.
Core Scientific director Jeffrey David Booth received 18,575 restricted stock units of common stock on February 4, 2026, as reported in a Form 4 filing. The grant was priced at $0 per share and will vest in full on February 3, 2027, if he continues serving as a non-employee director through that date. Following this award, Booth beneficially owns 214,262 shares of Core Scientific common stock directly.
Core Scientific, Inc. director Elizabeth Crain received a grant of 18,575 shares of common stock as restricted stock units. The award was reported as acquired at a price of $0 per share on February 4, 2026, increasing her directly held beneficial ownership to 65,348 shares.
The RSUs will vest in full on February 3, 2027, if she continues to serve as a non-employee director through that date. Until vesting, the units represent a right to receive shares rather than currently transferable stock.
Core Scientific, Inc. director Rozov Yadin reported an award of 18,575 shares of common stock on February 4, 2026, coded as an acquisition at a price of $0 per share. This reflects a grant rather than an open-market purchase.
The award represents a restricted stock unit grant that will vest in full on February 3, 2027, if Yadin continues to serve as a non-employee director through that date. After this grant, Yadin beneficially owns 454,162 shares of Core Scientific common stock in direct ownership.
Core Scientific director Eric Stanton Weiss received a new equity grant. On February 4, 2026, he was awarded 18,575 shares of Core Scientific common stock at a price of $0 per share, bringing his directly held stake to 245,262 shares.
The award is structured as restricted stock units that will vest in full on February 3, 2027, provided Weiss continues to serve the company as a non-employee director through that date.
Core Scientific, Inc. CEO and director reported an amendment to a prior insider transaction report. On January 29, 2026, 274,554 shares of common stock were withheld at $18.79 per share to cover tax obligations from vesting restricted stock units. After this withholding, the reporting person beneficially owned 4,131,150 shares directly. The amendment corrects an earlier filing that had inadvertently reported 274,404 shares withheld on January 23, 2026.
Core Scientific CEO Adam Taylor reported a tax-related share withholding. On 01/23/2026, 274,404 shares of Core Scientific common stock were withheld at a price of $18.79 per share to cover withholding tax obligations tied to the vesting of restricted stock units.
After this automatic withholding, Taylor directly beneficially owned 4,131,300 shares. The transaction is coded "F," indicating it was associated with equity award vesting rather than an open-market sale.
Two Seas Capital and related reporting persons filed an amended ownership report for Core Scientific, Inc., disclosing beneficial ownership of 22,472,467 shares of common stock, or about 7.2% of the company. This total includes 313,646 shares issuable upon exercise of warrants and options to purchase 5,077,600 shares at an exercise price of
The filing states the securities were acquired for investment purposes in the ordinary course of business because they were viewed as an attractive opportunity. The reporting persons may engage with Core Scientific’s management, board, other shareholders, and market participants on topics such as business strategy, capital allocation, governance, and environmental and social matters. They also indicate they may increase or decrease their position or use derivatives and hedging strategies to adjust their economic exposure over time.
Situational Awareness entities and two individuals filed a Schedule 13D reporting shared beneficial ownership of 17,682,918 shares of Core Scientific, Inc. common stock, representing 5.8% of the class based on 305,408,442 shares outstanding as of August 5, 2025. The filing states the Fund used $213,190,431.12 of working capital to acquire the shares, largely through a series of open-market purchases in July and August 2025 at prices reported between $13.189 and $14.9047 per share. The reporting persons say the stock was acquired for investment because they considered it undervalued and they reserve the right to buy, sell, hedge, or communicate with other stakeholders, but currently have no present plan to effect specific corporate changes.